Angioedema due to angiotensin-converting enzyme inhibitors

Immunopharmacology

Volumn 44, Issue 1-2, 1999, Pages 21-25

  Agostoni, Angelo ^a   Cicardi, Marco ^a   Cugno, Massimo ^a   Zingale, Lorenza C ^a   Gioffré, Daniela ^a   Nussberger, Jürg ^b  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Angioedema; Angiotensin converting enzyme inhibitors; Bradykinin; C1 inhibitor; High molecular weight kininogen

Indexed keywords

BRADYKININ; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ANGIONEUROTIC EDEMA; ARTICLE; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANGIONEUROTIC EDEMA; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CHILD; CHILD, PRESCHOOL; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; RECURRENCE;

EID: 0032734263     PISSN: 01623109     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0162-3109(99)00107-1     Document Type: Article

References (19)

1. Agah R., Bandi V., Guntupalli K.K. Angioedema: the role of ACE inhibitors and factors associated with poor clinical outcome. Intensive Care Med. 23:1997;793-796.
2. Agostoni A., Cicardi M. Contraindication to the use of ACE inhibitors in patients with C1-esterase inhibitor deficiency. Am. J. Med. 90:1991;278.
3. Anderson M.W., de Shazo R.D. Studies of the mechanism of angiotensin-converting enzyme (ACE) inhibitor-associated angioedema: the effect of an ACE inhibitor on cutaneous responses to bradykinin, codeine and histamine. J. Allergy Clin. Immunol. 85:1990;856-858.
4. Berrettini M., Lammle B., White T., Curd J., Griffin J.H. Detection of in vivo cleavage of high molecular weight kininogen in human plasma by immunoblotting with monoclonal antibodies. Blood. 68:1986;455-462.
5. Brown N.J., Ray W.A., Snowden M., Griffin M.R. Black americans have an increased rate of angiotensin convering enzyme inhibitor-associated angioedema. Clin. Pharmacol. Ther. 60:1996;8-13.
6. Brown N.J., Snowder M., Griffin M.R. Recurrent angiotensin-converting enzyme inhibitor-associated angioedema. JAMA. 278:1997;232-233.
7. Cugno M., Cicardi M., Coppola R., Agostoni A. Activation of factor XII and cleavage of high molecular weight kininogen during acute attacks in hereditary and acquired C1-inhibitor deficiency. Immunopharmacology. 33:1996;361-364.
8. Ebo D.G., Stevens W.J., Bosmans J.L. An adverse reaction to angiotensin-converting enzyme inhibitor in a patient with neglected C1 esterase inhibitor deficiency. J. Allergy Clin. Immunol. 99:1997;425-426.
9. Erdos E.G., Sloane E. An enzyme in human blood plasma that inactivates bradykinin and kallidin. Biochem. Pharmacol. 102:1962;256-260.
10. Gregory K.W.P., Davis R.C. Angioedema of the intestine. New Engl. J. Med. 334:1996;1641.
11. Nussberger J., Cugno M., Amstutz C., Cicardi M., Pellacani A., Agostoni A. Plasma bradykinin in angio-oedema. Lancet. 351:1998;1693-1697.
12. Pellacani A., Brunner H.R., Nussberger J. Plasma kinins increase after angiotensin-converting enzyme inhibition in human subjects. Clin. Sci. 87:1994;567-574.
13. Sabroe R.A., Black A.K. Angiotensin-converting enzyme (ACE) inhibitors and angio-oedema. Br. J. Derm. 136:1997;153-158.
14. Schweisfurth H., Reinhart E., Heinrich J., Brugger E. A simple spectrophotometric assay for carboxypeptidase N (kininase I) in human serum. J. Clin. Chem. Clin. Biochem. 21:1983;605-609.
15. Scott C.F., Shull B., Muller-Esterl W., Colman R.W. Rapid direct determination of low and high molecular weight kininogen in human plasma by particle concentration fluorescence immunoassay (PCFIA). Thromb. Haemostasis. 77:1997;109-118.
16. Shapira M., Silver L.D., Scott C.F., Schmaier A.H., Prograis L.J., Curd J.G., Colman R.W. Prekallikrein activation and high-molecular-weight-lininogen consumption in hereditary angioedema. New Engl. J. Med. 308:1983;1050-1054.
17. Sigler C., Annis K., Cooper K., Haber H., Van deCarr S. Examination of baseline levels of carboxipeptidase N and complement components as potential predictors of angioedema associated with the use of an angiotensin converting enzyme inhibitor. Arch. Dermatol. 133:1997;972-975.
18. Slater E.E., Merril D.D., Guess H.A., Rylance P.J., Cooper W.D., Inman W.H., Ewan P.W. Clinical profile of angioedema associated with angiotensin converting-enzyme inhibition. JAMA. 260:1988;967-970.
19. Vleeming W., van Amsterdam J.G.C., Stricker B.H.C., de Wildt D.J. ACE inhibitor-induced angioedema. Incidence, prevention and management. Drug Saf. 18:1998;171-188.